Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC
New Drug Application (NDA) based on data in TKI pre-treated patients from the global ALKOVE-1 Phase...
Publisher
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Nuvalent
- Region
- USA
- Scope
- Industry
- Published
- April 7, 2026
- Language
- EN
Topics
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
New Drug Application (NDA) based on data in TKI pre-treated patients from the global ALKOVE-1 Phase...
Source route
Continue on investors.nuvalent.com
Leave the platform to read the original full article on the publisher site.
Source: Nuvalent
Scope: Industry
Related coverage